{"id":46611,"date":"2022-07-27T10:01:44","date_gmt":"2022-07-27T08:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/"},"modified":"2022-07-27T10:01:44","modified_gmt":"2022-07-27T08:01:44","slug":"dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/","title":{"rendered":"Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market"},"content":{"rendered":"
\n

HYDERABAD, India & PRINCETON, NJ–(BUSINESS WIRE)–$RDY<\/a> #Bortezomib<\/a>–Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade\u00ae (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).\n<\/p>\n

<\/a><\/p>\n

\nThe Velcade\u00ae Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.\n<\/p>\n

\nDr. Reddy\u2019s Bortezomib for Injection is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.\n<\/p>\n

\nClick here for full prescribing information: https:\/\/www.drreddys.com\/pi\/dr-reddy-bortezomib-3.5mg-iv-sc-vial-leaflet.pdf<\/a>\n<\/p>\n

\nVelcade is a trademark of Takeda Pharmaceuticals U.S.A., Inc.\n<\/p>\n

\n*IQVIA Retail and Non-Retail MAT May 2022\n<\/p>\n

\nRDY-0722-430\n<\/p>\n

\nAbout Dr. Reddy\u2019s<\/b>: Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy\u2019s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy\u2019s operates in markets across the globe. Our major markets include \u2013 USA, India, Russia & CIS countries, and Europe. For more information, log on to: <\/b>www.drreddys.com<\/a>\n<\/p>\n

\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management\u2019s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency \/ severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and\/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers\u2019, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTOR RELATIONS<\/b>
AMIT AGARWAL
\n
amita@drreddys.com<\/a><\/span>\n<\/p>\n

\nMEDIA RELATIONS<\/b>
USHA IYER
\n
USHAIYER@DRREDDYS.COM<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HYDERABAD, India & PRINCETON, NJ–(BUSINESS WIRE)–$RDY #Bortezomib–Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade\u00ae (bortezomib) Injection, in the U.S. market approved by the U.S. Food and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46611","6":"format-standard","7":"category-industry"},"yoast_head":"\nDr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HYDERABAD, India & PRINCETON, NJ–(BUSINESS WIRE)–$RDY #Bortezomib–Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade\u00ae (bortezomib) Injection, in the U.S. market approved by the U.S. Food and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-27T08:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220727005417\/en\/1525831\/21\/drreddyslogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market\",\"datePublished\":\"2022-07-27T08:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005417\\\/en\\\/1525831\\\/21\\\/drreddyslogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/\",\"name\":\"Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005417\\\/en\\\/1525831\\\/21\\\/drreddyslogo.jpg\",\"datePublished\":\"2022-07-27T08:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005417\\\/en\\\/1525831\\\/21\\\/drreddyslogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005417\\\/en\\\/1525831\\\/21\\\/drreddyslogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market - Pharma Trend","og_description":"HYDERABAD, India & PRINCETON, NJ–(BUSINESS WIRE)–$RDY #Bortezomib–Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade\u00ae (bortezomib) Injection, in the U.S. market approved by the U.S. Food and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-27T08:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220727005417\/en\/1525831\/21\/drreddyslogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market","datePublished":"2022-07-27T08:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/"},"wordCount":534,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005417\/en\/1525831\/21\/drreddyslogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/","url":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/","name":"Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005417\/en\/1525831\/21\/drreddyslogo.jpg","datePublished":"2022-07-27T08:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220727005417\/en\/1525831\/21\/drreddyslogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220727005417\/en\/1525831\/21\/drreddyslogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-bortezomib-for-injection-3-5-mg-single-dose-vial-in-the-u-s-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46611"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46611\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}